Oncogene for aggressive breast cancer identified

Article

British and Canadian researchers have discovered a gene, ZNF703, that can cause an aggressive form of breast cancer. The gene is overactive in approximately 1 in 12 breast cancers.

British and Canadian researchers have discovered a gene, ZNF703, that can cause an aggressive form of breast cancer. The gene is overactive in approximately 1 in 12 breast cancers.

By examining gene activity in 1,172 tumor samples and laboratory-grown breast cancer cells, investigators from Cancer Research UK’s Cambridge Research Institute and the British Columbia Cancer Agency, Vancouver, eliminated genes until only the ZNF703 gene remained within a region on chromosome 8 that was overactive in all test samples. In 2 patients, it was the only overactive gene, indicating that it was driving growth of the cancer.

Researchers suggest that this discovery might lead to development of new breast cancer drugs that target tumors in which overactivity of ZNF703 is detected.

The study was published online January 31 in EMBO Molecular Medicine.

Recent Videos
Baher Mankabady, MD, highlights safety of buprenorphine against OUD in pregnancy | Image Credit: linkedin.com.
Devon Ramaeker, MD
Elizabeth Gandee, APRN-CNP, highlights gaps in women's menopause knowledge | Image Credit: wexnermedical.osu.edu
Doula highlights how postpartum care is failing new mothers | Image Credit: linkedin.com
Nicky Herrick MD; and Anushree Agarwal, MD, MBBS, highlight their study on cardiac arrhythmias in pregnancy | Image Credit: © Igor Borodin - stock.adobe.com.
Lisa Becht, MD, FACOG, sheds light on fertility awareness | Image Credit: havingbabies.com.
First US national HPV conference highlights advances in cancer prevention | Image Credit: uchealth.com.
Mitchell Creinin, MD, reports estetrol pill eases menstrual symptoms | Image Credit: health.ucdavis.edu
1 expert is featured in this series.
Susanna Mitro, PhD, reveals ethnic disparities in uterine fibroid diagnosis | Image Credit: divisionofresearch.kaiserpermanente.org.
© 2025 MJH Life Sciences

All rights reserved.